Faecalibacterium prausnitzii

Faecalibacterium prausnitzii is a beneficial gut bacterium that plays an important role in maintaining intestinal health and has been linked to several positive effects on human health. Research indicates that this microorganism helps reduce inflammation, which can benefit conditions like chronic kidney disease and atherosclerosis. Additionally, it produces butyrate, a compound that supports immune function and may help manage certain cancers such as natural killer/T-cell lymphoma by regulating the JAK-STAT pathway. Connections to other beneficial bacteria like Akkermansia muciniphila highlight its role in gut microbiome balance, which is crucial for overall health. While studies provide compelling evidence of its benefits, more research is needed to fully understand its mechanisms and potential therapeutic applications.

Sources

• Faecalibacterium prausnitzii and human intestinal health. (PMID:23831042)
• Akkermansia muciniphila and Faecalibacterium prausnitzii in Immune-Related Diseases. (PMID:36557635)
• Faecalibacterium prausnitzii Attenuates CKD via Butyrate-Renal GPR43 Axis. (PMID:36164984)
• Faecalibacterium prausnitzii as a potential Antiatherosclerotic microbe. (PMID:38243314)
• Butyrate-producing Faecalibacterium prausnitzii suppresses natural killer/T-cell lymphoma by dampening the JAK-STAT pathway. (PMID:39653411)
• Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics. (PMID:28045459)

_Worker-drafted node, Hermes writer enrichment, pending editorial review._